Longevity Companies

Lifespan extension for companion animals. Life Biosciences portfolio company

Boston, MA

proteostasis regulation, proteasome

Berlin, MA

Targeting TGF-beta family to treat a variety of diseases

Sudbury, MA

Modulating lysosome ion channels to improve autophagy

Cambridge, MA

Drugs that stimulate autophagy

Cambridge, MA

GDF11 "young blood" factor

Newton, MA

Device based filtering and modifying of cerebrospinal fluid to treat neurodegenerative disease.

Newburyport, MA

SIRT6 activators for DNA repair

Cambridge, MA

Peptide discovery platform to treat neurodegenerative disease (in silico)

Newton, MA

epigenetic reprogramming to rejuvenate / regenerate optic nerve

Boston, MA

Reversing age-related decline of fertility

Coogee, MA

DisCo

Boston, MA

Rejuvenation genes and reprogramming with applications in skin

Boston, MA

Mitochondrial targeted therapeutics for rare disease and aging.

Cambridge, MA

mTORC1 inhibitors and activators

Cambridge, MA

Targeting mitochondria genome, mtDNA express, and mitochondria quality control.

Waltham, MA

Defunct. mTORC1 pathway. Merged with Adicet. Programs discontinued.

Boston, MA

Muscle regeneration. Drugs that target the latent form of my-statin.

Cambridge, MA

Drugs that activate chaperone-mediated autophagy

Boston, MA

Elamipretide peptide to stabilize cardiolipin and reduce peroxidation

Needham, MA

Drugs to modulate mitophagy to treat disease. USP inhibitors

Cambridge, MA

NAD+ boosting drugs

Cambridge, MA